26-28 February 2010
Cannes, France
InterContinental Carlton Cannes

Chairs:

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Eva Kimby, MD, PhD
Karolinska University Hospital
Stockholm, Sweden

2nd Announcement
Dear Colleague,

We are pleased to invite you to attend the 6th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice, which will be held 26-28 February 2010, in beautiful and historic Cannes, France!

The focus of the 2010 Congress is to provide a forum to review state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and in this year’s special session, acute lymphocytic leukemia, as well as give attendees the opportunity to exchange ideas with world-renowned opinion leaders in hematologic malignancies.

Last year’s congress, held in Munich, Germany, was attended by hematology, oncology, and other healthcare-related professionals from nearly 40 countries, all of whom increased their knowledge and have changed their approach to disease management. Their highly positive review of the educational content, quality of speakers, and presentation excellence attests to the overall satisfaction of the attendees—and the value of continuing with a comprehensive update on hematologic oncology management.

To complement the exceptional scientific experience this Congress brings, Cannes offers the perfect educational backdrop, with its Mediterranean location, quiet charm, and dedication to the arts.

We hope you will join us in this beautiful and historic city for a stimulating and enjoyable Congress, as this meeting promises to be an exciting, interactive and educational experience for all attendees!

Sincerely,

Bertrand Coiffier, MD, Chair
Eva Kimby, MD, PhD, Chair

Faculty
Andrea Biondi, MD
Hospital S. Gerardo
Via Pergolesi, Italy
Joan Bladé, MD
University of Barcelona
Hospital Clinic
Barcelona, Spain
Christian Buske, MD
University of Munich
Munich, Germany
Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France
Carlo Croce, MD
Ohio State University
Columbus, Ohio
Francesco d’Amore, MD, PhD
Aarhus University Hospital
Aarhus, Denmark
Martin Dreyling, MD, PhD
University Hospital Munich
Munich, Germany
Andreas Engert, MD
University Hospital of Cologne
Cologne, Germany
Christophe Fermé, MD
Institut de Cancérologie
Gustave Roussy
Villejuif, France
Randy D. Gascoyne, MD
British Columbia Cancer Agency
Vancouver, Canada
Christian Geisler, MD, PhD
Nordic Lymphoma Group
Copenhagen, Denmark
Michele Ghielmini, MD
Oncologica Medica
Bellinzona, Switzerland
Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
Milan, Italy
Nicola Gökbüget, MD
Goethe University Hospital
Frankfurt, Germany
Corinne Haion, MD
Henri Mondor Hospital
Créteil, France
Michael Hallek, MD
University of Cologne
Cologne, Germany
Jean-Luc Harousseau, MD
University Hospital
Hotel-Dieu
Nantes, France
Dieter Hoelzer, MD
University of Frankfurt
Frankfurt, Germany
Peter Johnson, MD
Cancer Research UK Clinical Centre
South Hampton, United Kingdom
Eva Kimby, MD, PhD
Karolinska University Hospital
Stockholm, Sweden
Veronique LeBlond, MD
University of Pierre and Hospital Pitie-Salpetriere
Paris, France
Emili Montserrat, MD
University of Barcelona
Barcelona, Spain
Nicolas Mounier, MD
CHU de Nice
Hôpital de L’archet
Nice, France
Antonio Palumbo, MD
University of Torino
Torino, Italy
Michael Pfreundschuh, MD
University of Saarland
Homburg, Germany
Andreas Rosenwald, MD
University of Würzburg
Würzburg, Germany
Gilles Salles, MD
Université Claude Bernard Lyon
Hôpitaux Civils de Lyon
Lyon, France
Jesus F. San Miguel, MD
University of Salamanca
Salamanca, Spain
Norbert Schmitz, MD
Asklepios Klinik St. George
Hamburg, Germany
Lena Specht, MD, PhD
Copenhagen University Hospital
Copenhagen, Denmark
Herve’ Tilly, MD
Groupe d’Etudes de Lymphomes de L’adulte
Rouen, France
Rien H.J. van Oers, MD
Academic Medical Center
Amsterdam, The Netherlands
Pier Luigi Zinzani, MD
University of Bologna
Bologna, Italy
Continuing Medical Education

Educational Objectives
After successful completion of this continuing medical education activity, participants should be able to:

- Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and related diseases
- Discuss the role of the microenvironment in the development and disease progression of chronic lymphocytic leukemia and follicular lymphoma
- Evaluate how the disease risk and age of a patient determines optimal management and the course of therapy for lymphoma
- Describe the biology, management and current treatment options of myeloma and lymphoma for front-line, salvage, and maintenance therapy as well as therapeutic strategies to overcome relapsed/refractory disease
- Evaluate the feasibility of chemotherapy, radioimmunotherapy, targeted therapy, and transplantation as treatment options for various stages of indolent lymphoma
- Debate whether autologous or allogeneic stem cell transplantation is appropriate for management of mantle cell lymphoma
- Employ current and novel strategies to improve diagnosis and treatment outcomes in aggressive non-Hodgkin’s lymphomas
- Determine whether specific subtypes of aggressive NHL should be treated in the same manner
- Positively impact patient outcomes by assimilating diagnostic, prognostic and molecular approaches toward optimal stratification for current and novel treatment options in acute lymphoblastic leukemia

Who Should Attend
This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, oncology fellows, oncology nurses, internists and other physicians, physicians-in-training, and healthcare professionals involved in and/or interested in lymphoma, myeloma, related plasma cell disorders, and in the special session of 2010, acute lymphoblastic leukemia.

Corporate Support
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted</td>
<td>€299</td>
</tr>
<tr>
<td>If payment received by 8 December 2009</td>
<td></td>
</tr>
<tr>
<td>Regular</td>
<td>€399</td>
</tr>
<tr>
<td>If payment received by 18 February 2010</td>
<td></td>
</tr>
<tr>
<td>Full/Onsite</td>
<td>€499</td>
</tr>
<tr>
<td>If payment received after 18 February 2010</td>
<td></td>
</tr>
<tr>
<td>Nurses/Residents/Students*</td>
<td>€199</td>
</tr>
<tr>
<td>*proof of eligibility must accompany registration</td>
<td></td>
</tr>
</tbody>
</table>

Praise from Your Colleagues:

“Conference hard to improve – it was very good”
“I found this meeting very enjoyable”
“Excellent conference”
“Thank you… interesting meeting”
“Keep up the good work”
“Thank you very much to Imedex”
“Continue in the same way!”
“Well organized”
“Thank you for high quality symposium”
“Excellent meeting covering majority of interesting and important topics in malignant hematology”
**Friday, 26 February 2010**

**13:00** Welcome and introduction

**Session I: Myeloma**
Moderator: Jesus San Miguel, MD and Bertrand Coiffier, MD

**13:05** Overview of newly diagnosed patients
Speaker Invited

**13:20** DEBATE: First-line treatment in the transplant eligible patient
Jean-Luc Harousseau, MD
Antonio Palumbo, MD

**13:50** Current and emerging options for relapsed myeloma
Jesus San Miguel, MD

**14:10** DEBATE: Best salvage therapy for the relapsed patient
Jesus San Miguel, MD and Speaker Invited

**14:40** The role of VTE prophylaxis in myeloma
Antonio Palumbo, MD

**15:00** Summary of the IMW consensus on response criteria and relevant outcomes
Joan Blade', MD

**15:15** Chair take-home points for the clinician

**15:20** Break

**Session II: Chronic Lymphocytic Leukemia**
Moderator: Michael Hallek, MD and Eva Kimby, MD, PhD

**15:40** MicroRNA signatures in CLL
Carlo Croce, MD

**16:00** Monoclonal B-cell lymphocytosis and CLL
Paolo Ghia, MD

**16:20** Case discussion: Optimal management of the low risk patient
Michael Hallek, MD

**16:50** Case discussion: Optimal therapy for the high risk patient
Veronique Leblond, MD

**17:20** DEBATE: Management of the double-refractory patient
Michael Hallek, MD and Emili Montserrat, MD

**17:50** Panel discussion

**18:00** Chair take-home points for the clinician and adjourn

**Saturday, 27 February 2010**

**Session III: Follicular Lymphoma**
Moderator: Gilles Salles, MD and Eva Kimby, MD, PhD

**9:00** Role of the microenvironment in FL
Randy Gascoyne, MD

**9:20** Overview of maintenance therapy
Gilles Salles, MD

**9:40** DEBATE: Is follicular lymphoma curable?
Michele Ghielmini, MD (no)
Christian Buske, MD (yes)

**10:10** DEBATE: The role of stem cell transplant in patients with relapsed follicular lymphoma
Bertrand Coiffier, MD (for)
Rien van Oers, MD (against)

**10:40** Panel discussion and chair take-home points for the clinician

**10:50** Break

**Session IV: Mantle Cell Lymphoma**
Moderator: Martin Dreyling, MD and Eva Kimby, MD, PhD

**11:10** Biology of mantle cell lymphoma
Andreas Rosenwald, MD

**11:30** Case discussion: Mantle cell lymphoma therapy in the young and old patient
Martin Dreyling, MD

**11:50** Maintenance therapy after first and second-line therapy in MCL
Michele Ghielmini, MD

**12:10** DEBATE: Autologous versus allogeneic transplantation in mantle cell lymphoma
Christian Geisler, MD (auto)
Norbert Schmitz, MD (allo)

**12:40** Panel discussion and chair take-home points for the clinician

**13:00** Lunch

**Session V: Aggressive B-cell Non-Hodgkin’s Lymphoma**
Moderator: Bertrand Coiffier, MD and Michael Pfreundschuh, MD

**14:30** Biology and treatment of bulky and mediastinal large B-cell lymphoma
Pier Luigi Zinzani, MD

**14:50** DEBATE: Prevention and treatment of central nervous system disease
Michael Pfreundschuh, MD
Corinne Haioun, MD

**15:20** DEBATE: Improving high-risk DLCBL in both the young and elderly
Bertrand Coiffier, MD
Michael Pfreundschuh, MD

**15:50** PROPOSITION: Same treatment for germinal centre (GC) and non-GC patients?
Peter Johnson, MD (no)
Herve’ Tilly, MD (yes)
Sunday, 28 February 2010

Session VII: Hodgkin’s Disease
Moderator: Andreas Engert, MD
9:00 Overview: Improving efficacy, reducing toxicity of localized MD
Andreas Engert, MD
9:20 Radiation in Hodgkin’s disease
Lena Specht, MD, PhD
9:40 Treatment of relapsing patients
Christophe Fermé, MD
10:00 Allogeneic transplantation
Norbert Schmitz, MD
10:20 Panel discussion and chair take-home points for the clinician
10:30 Break

Session VIII: SPECIAL SESSION – Acute Lymphoblastic Leukemia
Moderator: Dieter Hoelzer, MD
11:00 Recent diagnostic approaches and molecular genetics in ALL
Robin Foà, MD
11:25 New treatment options in adult ALL including targeted therapy
Dieter Hoelzer, MD
11:50 Update on achievements in childhood ALL
Andrea Biondi, MD
12:15 Minimal residual disease: Prognostic parameters to stratify and treat ALL
Nicola Gökbuget, MD
12:40 Panel discussion and chair take-home points for the clinician
13:00 Adjourn

Hotel Accommodations
InterContinental Carlton Cannes, 58, Bd. La Croisette, BP 355, Cannes, 06444, France
Tel: +33 4 93 64 0066

Built in 1921, the InterContinental Carlton Cannes has evolved throughout the years as a timeless monument to a place which, day by day, combines refined service and well-being. The hotel is located on the famous Croisette Avenue and close to the Cannes Palais des Festivals, which offers breathtaking views of the Mediterranean Sea.

For the convenience of attendees, a limited number of rooms have been reserved until 19 January 2010 at a discounted rate of €150.00 single occupancy or €275.00 double occupancy. Room rates include VAT and breakfast buffet. This rate is not guaranteed outside the Congress dates or after 19 January 2010.

Italian Participants
Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:
Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel: +39 055 600 555
Fax: +39 055 600 978

Registration & Hotel
Register: You may register online by 18 February 2010 by visiting our website at www.imedex.com or by calling Imedex at +1 (678) 242 0906. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than 18 February 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: EHema A138.01. An attendee is not registered until full payment is received.


Registration Fee Inclusions:
Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 18 February 2010. The amount of registration fees remitted, minus a $60 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 18 February 2010.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this Congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as “Imedex”). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, Imedex EXPRESSLY DISCLAIMS ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. Imedex further makes no representations or warranties about the accuracy, reliability, completeness or timeliness of the content or any material presented.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

© 2009 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
Check if you require special facilities or assistance and attach a note with specific details and requirements.

### PAYMENT METHOD

- American Express
- MasterCard
- Visa
- Check or wire in the amount of: €

*(To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges.)*

- Card No. ____________________________________________
- Exp. Date: ___________ / ___________
- Cardholder’s Name: __________________________________
- Signature: ___________________________

Note: Registrants that pay with American Express will be charged in the USD equivalent. This is a policy of American Express. More information may be found at www.oanda.com.

Keep a copy for your records.